1 Data from 5,171 patients were
assessable.
2 tal of 30 patients were enrolled and 28 were
assessable.
3 Three patients (6%) were not
assessable.
4 rty-nine patients (25 with M1c disease) were
assessable.
5 A total of 644 patients were
assessable.
6 195; BCT, n = 200) were deemed eligible and
assessable.
7 atients; thus, 140 patients in each arm were
assessable.
8 One died within 72 hours and was not
assessable.
9 219 of 227 enrolled patients were
assessable.
10 There were 26 patients enrolled; 18 were
assessable.
11 ts were enrolled onto the study, and 53 were
assessable.
12 3) had at least 1 subcompetency rated as not
assessable.
13 219 of these 227 enrolled patients were
assessable.
14 1,551 randomly assigned patients, 1,524 were
assessable.
15 ons; of those, 54 patients were eligible and
assessable.
16 ach specific cytogenetic abnormality was not
assessable.
17 Forty-nine patients were entered and 43 were
assessable (
12% stage IB; 37% stage II; and 52% stage II
18 tients who underwent randomisation, 217 were
assessable 2 h after the start of acetylcysteine treatme
19 A total of 651 patients were
assessable (
227 randomly assigned to tamoxifen and 424 r
20 Of 682 patients enrolled, 644 patients were
assessable and analyzed.
21 nts had no PSA response and 6 (15%) were not
assessable and assumed to be nonresponders.
22 Tissue was
assessable and ER and/or PgR positivity confirmed centra
23 ntle cell lymphoma were enrolled and 69 were
assessable and were included in the final analysis.
24 and 7, at least 12 patients per cohort were
assessable,
and the dose level with prospectively define
25 100% histologic cure was achieved in 9 of 9
assessable animals without detectable radiation damage t
26 More than 90% of 26
assessable archival tumor specimens were highly positive
27 (arm A, n = 41; arm B, n = 43), and 72 were
assessable (
arm A, n = 37; arm B, n = 35).
28 of patients assigned erlotinib and who were
assessable at 1 month developed first-cycle rash, which
29 d 132 (31%) patients, respectively, were not
assessable at 2 months and were counted as missing data
30 F and survival were compared in 135 patients
assessable at 2 months with tumor shrinkage below (poor
31 One hundred sixteen patients were
assessable at 3 months postoperatively.
32 and Human Development to relate risk factors
assessable at or before birth to the likelihood of survi
33 one individual with thymic carcinoma was not
assessable because she died.
34 ted ascending aortic geometries that are not
assessable by current echocardiographic measures.
35 ed C1 and C2, respectively) and were MFC-MRD
assessable by LAIP detection in CR bone marrow for at le
36 Of nine patients
assessable by PET,responses were complete in five patien
37 acteristics and patient-related risk factors
assessable by the clinician at patient presentation can
38 ic modifications of mucus contrasts that are
assessable by using a noninvasive, contrast material-fre
39 Of the 26 measures, 10 are readily
assessable by using cancer registry data.
40 ee hundred eighty-five patients patients had
assessable CA 19-9 levels.
41 Of 910 total
assessable cases, 112 of 488 ErbB-2-positive cases (23%)
42 Effusions were exudative in 78% of the
assessable cases.
43 xclusively based on objective preoperatively
assessable characteristics and can be rapidly and easily
44 Of 294/315
assessable children, 15/294 had pure spasticity, leaving
45 ry tumour samples, of whom 865 (50%) had two
assessable cores (445 in the control groups and 420 in t
46 seen in 51 of 73 patients and in 107 of 209
assessable coronary arteries.
47 The percentage of
assessable coronary artery segments was 98.6% (1196 of 1
48 er D-serine (n=20) or placebo (n=24); 35 had
assessable data (15 D-serine, 20 placebo).
49 ble patients were enrolled, of whom 1941 had
assessable data (968 in the capecitabine alone group and
50 y and either gefitinib or erlotinib, and had
assessable disease (RECIST 1.1) and tumour tissue sample
51 Ten of 46 patients with
assessable disease had a partial response, and these res
52 ne included FOLFOX4 treatment, patients with
assessable disease, or a single site of metastasis.
53 y Group performance status of 2 or less; had
assessable disease; were not suitable to receive any est
54 CU days of observation in which delirium was
assessable (
e.g., patient was noncomatose), with a total
55 NSCLC), and that this determination might be
assessable early on during therapy.
56 The proportions of patients having
assessable EORTC QLQ-C30 and EQ-5D questionnaires at bas
57 published primary outcome with 90% of those
assessable favoring a statistically positive result.
58 Among 33 patients
assessable for a cytogenetic response, 17 (52%) experien
59 led and given cabozantinib; 25 patients were
assessable for a response.
60 All treated patients were
assessable for a response.
61 prised the full analysis set and were deemed
assessable for activity.
62 ylphenidate and 53 in the placebo group were
assessable for analysis.
63 50 patients were
assessable for both toxic effects and response; eight ad
64 erapy for at least 1 year, 173 patients were
assessable for cardiac toxicity.
65 30 patients were
assessable for change in lean body mass, which increased
66 Of the 12 patients who were
assessable for chemotherapeutic response (pre-RT), the o
67 Of 104 patients recruited, 100 patients were
assessable for clinical benefit prior to planned nephrec
68 One hundred ten patients were
assessable for clinical efficacy.
69 Of 42 patients enrolled, 39 were
assessable for clinical outcome and DC analysis.
70 Of 43 patients
assessable for clinical response, two patients had confi
71 Among 73 patients
assessable for clonal evolution during stable chronic ph
72 ten in the safety expansion group); 31 were
assessable for efficacy (<400 mg, n=16; 400 mg, n=15).
73 A total of 133 patients were
assessable for efficacy and safety.
74 All patients were
assessable for efficacy and safety.
75 Sixteen of 23 patients
assessable for efficacy in the nonrandomized single-arm
76 in cohort 1 and 62 patients in cohort 2 were
assessable for efficacy.
77 patients were enrolled and 30 patients were
assessable for efficacy.
78 pezil group and 56 in the placebo group were
assessable for final analysis.
79 to treatment in the CLARITY study, 1192 were
assessable for freedom from disease activity at 96 weeks
80 f treatment received but restricted to those
assessable for hearing loss.
81 hs of radiographic follow-up were considered
assessable for local control.
82 Forty-nine discrete lesions were
assessable for local control.
83 Fifty lesions were
assessable for local control.
84 enty-one patients were included, and 19 were
assessable for metabolic response evaluation with FLT-PE
85 gy Study 9047 (1990-2000), 560 children were
assessable for ploidy and MYCN amplification.
86 Forty-seven patients
assessable for PN received a median of five cycles of th
87 ved 400 mg, and 33 who received 1400 mg were
assessable for PSA response at 12 weeks.
88 However, among 40 patients
assessable for radiologic response, none experienced par
89 242 patients enrolled, 224 were eligible and
assessable for response (106 and 118 patients in the con
90 Four of 18 patients
assessable for response (22%; 95% CI, 2% to 42%) achieve
91 Forty-three enrolled patients were
assessable for response and safety.
92 Seven of 30 registrants who were
assessable for response had a partial response, and six
93 34/216) and 8% (18/214) of patients who were
assessable for response in these respective groups had a
94 Twenty-two patients were
assessable for response, including 14 complete responses
95 Of 19 patients treated for refractory NB and
assessable for response, nine showed evidence of disease
96 Of 161 patients
assessable for response, one patient with hepatoblastoma
97 Among the 49 patients
assessable for response, the objective response rate was
98 ents assessable for toxicity and 20 patients
assessable for response.
99 Thirty patients were
assessable for response.
100 ) had progressive disease, and five were not
assessable for response.
101 nsformed (20%) disease were treated; 74 were
assessable for response.
102 al of 126 patients were treated and 113 were
assessable for response.
103 were enrolled; 27 were eligible, and 26 were
assessable for response.
104 ctory myeloma were enrolled, 34 of whom were
assessable for response.
105 tients were entered onto the study, with 103
assessable for response.
106 female) were entered onto the trial and were
assessable for response.
107 All 17 patients were
assessable for response.
108 Sixty-six patients were
assessable for response.
109 Of the 47 patients
assessable for safety, grade 3 or 4 hematologic events w
110 atients, 48 underwent two MRIs; 44 MRIs were
assessable for study end points.
111 Four hundred four patients were
assessable for surgical outcomes.
112 Forty-eight patients were entered; all were
assessable for survival, and 47 were assessable for toxi
113 Of these, 104 participants were
assessable for the primary endpoint (sodium thiosulfate,
114 We deemed patients as
assessable for the primary endpoint in the phase 1 porti
115 175 (79%) participants were
assessable for the primary outcome in the mITT populatio
116 Forty-two of 44 patients were
assessable for this analysis.
117 A total of 230 patients were
assessable for this analysis: 99 patients with severe la
118 -non-amplified disease; 55 patients were not
assessable for TOP2A status.
119 Dec 31, 2015, 23 patients were enrolled and
assessable for toxic effects after completing accrual.
120 the study at levels 1 to 4, with 18 patients
assessable for toxicity and 20 patients assessable for r
121 toma and no prior ASCT were entered; 22 were
assessable for toxicity and response.
122 ll were assessable for survival, and 47 were
assessable for toxicity and response.
123 icity) or 260 mg/m2/d (seven enrolled, three
assessable for toxicity) of temozolomide.
124 ved either 200 mg/m2/d (nine enrolled, three
assessable for toxicity) or 260 mg/m2/d (seven enrolled,
125 Fifteen patients (12 fully
assessable for toxicity) with first or later CD22-positi
126 21 years), were enrolled, and 42 were fully
assessable for toxicity.
127 , and 18 completed one course and were fully
assessable for toxicity.
128 ere enrolled, and 18 (12 with sarcomas) were
assessable for toxicity.
129 Twenty-three patients were enrolled and
assessable for toxicity.
130 years), were enrolled, of whom 29 were fully
assessable for toxicity.
131 y-three solid tumor and 17 NF1 patients were
assessable for toxicity.
132 one patients were enrolled; 32 patients were
assessable for toxicity.
133 Thirty patients received treatment and were
assessable for toxicity.
134 Thirty-five patients were enrolled and were
assessable for toxicity; one patient had MCL by histolog
135 Five patients were not
assessable for tumor response.
136 48 patients were
assessable for tumour response.
137 patients for whom treatment and outcome were
assessable had full (three patients) or partial (nine pa
138 -modality, and boost therapy, 37 (82%) of 45
assessable high-risk patients achieved a complete respon
139 the surgical ICU; 227 of 415 (55%) long-stay
assessable ICU patients were weak; 122 weak patients wer
140 Patients were
assessable if eligible for the MA.27 trial, received som
141 ive analysis of 372 breast cancer cases with
assessable immunohistochemical data for ER, PR, and Her-
142 The combined end point was
assessable in 155 (97%) patients.
143 y to SEE for functional recovery but was not
assessable in 25% of patients.
144 Treatment effects and outcome were
assessable in 501 (median follow-up 24 months, range 4-1
145 EGFR FISH was
assessable in 76 patients with available tumor tissue an
146 EGFR FISH was
assessable in 976 patients and 400 patients (41%) were E
147 logic conditions but has not been previously
assessable in population cohorts.
148 6%) in the CBT group, whereas 135 (61%) were
assessable in the PP population in the BA group compared
149 A rating of "not
assessable"
indicated insufficient information to evalua
150 Median follow-up for
assessable lesions was 15.4 months (range, 6 to 48 month
151 Median follow-up for
assessable lesions was 16 months (range, 6 to 54 months)
152 acy analysis population (patients with fully
assessable locally advanced disease and all those with m
153 All 15
assessable margins were clear on CLI and histopathology.
154 To identify a powerful and easily
assessable miRNA bio-marker of prognosis and survival, w
155 patients where radial margin status was not
assessable (
n = 16).
156 ressive disease (PD), and seven patients not
assessable (
NA).
157 ble disease (SD) for 8 or more courses in 30
assessable neuroblastoma patients.
158 the new sensor array was tested for an easy
assessable objective: coffee ageing during storage.
159 neteen of 122 randomly assigned patients had
assessable outcomes.
160 A total of 136 eligible and
assessable patients (101 untreated, 35 previously treate
161 ith GBM (95% CI, 0.1% to 15%) and five of 32
assessable patients (16%) with anaplastic glioma (95% CI
162 73.9) in the capecitabine group and 18 of 35
assessable patients (51.4%, 39.4-63.4) in the gemcitabin
163 There were 1,059
assessable patients (526 erlotinib; 533 placebo).
164 After 9 months, 22 of 35
assessable patients (62.9%, 80% CI 50.6-73.9) in the cap
165 Four of six
assessable patients (67%) with DLBCL achieved an OR, inc
166 Responses were observed in five of six
assessable patients (83%) at the MTD.
167 Fifteen (25%) of 59
assessable patients (95% CI, 16% to 37%) had objective r
168 urable responses were seen in 19 (76%) of 25
assessable patients (95% exact binomial CI, 55% to 91%),
169 Between 1987 and 1991, 456
assessable patients (median age, 70 years) were enrolled
170 ot complete the cognitive screen, leaving 85
assessable patients (median age, 72 years).
171 Of 13
assessable patients (nine with adult T-cell leukaemia-ly
172 rtial responses seen in seven of 25 response-
assessable patients (overall response 28%, 95% CI 12-49)
173 Twenty-three (49%) of 47
assessable patients achieved a complete response (CR) to
174 Two (8%) of 26
assessable patients achieved a partial response.
175 Twelve (19%) of 62
assessable patients achieved an objective confirmed resp
176 In untreated AML, four of nine
assessable patients achieved CR.
177 Three of 13
assessable patients achieved objective radiographic and/
178 Pseudoprogression was observed in 37% of
assessable patients and may have had an impact on estima
179 In phase II, 8 (10%) of 84 response-
assessable patients attained objective antitumor respons
180 All
assessable patients engrafted, with median time for neut
181 d five partial responses were achieved in 35
assessable patients for an overall response rate of 17.1
182 11 (18%) of 60
assessable patients had a confirmed objective response,
183 or 0.4 mg/kg every 6 weeks), 11 (18%) of 60
assessable patients had a confirmed objective response.
184 te toxicities and 131 controls; thus, 43% of
assessable patients had a severe late toxicity.
185 Six of 22
assessable patients had complete or partial response, an
186 Nine (20%) of 46
assessable patients had confirmed partial responses unti
187 sistant neuroblastoma, and seven (50%) of 14
assessable patients had response or disease stabilizatio
188 sponses were needed in the first 20 response-
assessable patients in each of the five tumour cohorts.
189 red orally daily to groups of at least three
assessable patients in escalating doses of 50, 75, 100,
190 An interim analysis of the first 23
assessable patients in the first cohort treated at 420 m
191 31 (76%) of 41
assessable patients in the fluorouracil group had grade
192 34 (85%) of 40
assessable patients in the paclitaxel group had grade 3-
193 Responses among 35
assessable patients included 10 partial responses (28.6%
194 Prognostic factors in
assessable patients included advanced stage (III/IV) in
195 Ninety-nine
assessable patients received 6 cycles of doxorubicin 25
196 Fourteen
assessable patients received 75 courses.
197 Fifty-four
assessable patients received paclitaxel consolidation.
198 Forty-five
assessable patients received protocol therapy.
199 Treatment of six
assessable patients resulted in one venous thrombosis; t
200 d 10.6 +/- 4.4 months, with nine of 16 (56%)
assessable patients surviving 1 year or longer.
201 Twenty-three
assessable patients taking EIAEDs received tipifarnib in
202 For the 146
assessable patients treated with bexarotene, median age
203 edian follow-up time, the overall RR for 121
assessable patients was 16.5% (95% CI, 10% to 26%); the
204 dian age at the time of follow-up for the 20
assessable patients was 16.9 years (IQR 15.5-21.8).
205 The 5-year survival rate of the 76
assessable patients was 24% (median, 20 months).
206 The pCR rate for all
assessable patients was 26% in each arm.
207 Response rate in 141
assessable patients was 33% including 8% complete respon
208 an follow-up time for all 1,236 eligible and
assessable patients was 35.7 months.
209 The overall response rate for the 130
assessable patients was 39% (chemotherapy, 34%; chemoimm
210 The distribution of
assessable patients was: two of three in cohort 1, three
211 he response rate and disease control rate in
assessable patients were 36% and 82%, respectively.
212 he response rate and disease control rate in
assessable patients were 36% and 82%, respectively.
213 ion (CR2) rates at the end of block 1 in 117
assessable patients were 68% +/- 6% for ER (n = 63) and
214 Six hundred nineteen
assessable patients were analyzed.
215 A total of 553 consecutive
assessable patients were enrolled onto a treatment proto
216 5% confirmed overall response rate (ORR), 41
assessable patients were needed.
217 A total of 76
assessable patients were treated on this phase II trial,
218 Seventeen
assessable patients were treated.
219 Of the six
assessable patients who had declined the procedure, one
220 Of the 14
assessable patients who had successfully undergone ovari
221 tients who received 8 Gy vs 229 [66%] of 349
assessable patients who received 20 Gy; p=0.011) and dia
222 Two of six
assessable patients who received 56 mg/m(2) had reversib
223 days were lack of appetite (201 [56%] of 358
assessable patients who received 8 Gy vs 229 [66%] of 34
224 There were 303
assessable patients with a median follow-up of 68.4 mont
225 Of 11
assessable patients with AHWT, two had PR, one had SD, a
226 (arm A) or without oblimersen (arm B) in 56
assessable patients with chemotherapy-naive ES-SCLC.
227 Of 25
assessable patients with FHWT, 12 had partial response (
228 Between June 7, 2000, and Oct 24, 2007, 498
assessable patients with newly diagnosed ALL were enroll
229 Results One hundred eighty-five
assessable patients with one of 10 subtypes of sarcoma w
230 A total of 1,003
assessable patients with SLN metastasis had immediate (n
231 EFS) and overall survival (OS) estimates for
assessable patients with stage I AH (n = 29) were 69.5%
232 ND METHODS Four hundred twenty-two eligible,
assessable patients with stage IIIA/B NSCLC were treated
233 Of 23
assessable patients with thymic carcinoma, six (26%, 90%
234 Thirty-one
assessable patients with uveal melanoma demonstrated two
235 Five studies (comprising 1,716
assessable patients) compared a 5-HT(3) antagonist with
236 [CR] and 13 partial responses [PR] among 44
assessable patients).
237 For 23
assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had
238 Of 21
assessable patients, 11 (52%) responded: four with morph
239 Of the 23
assessable patients, 16 had stable disease as their best
240 In 68
assessable patients, 17 (25%) had grade 3 to 4 esophagit
241 Of 396
assessable patients, 202 were randomly allocated to rece
242 Of 29
assessable patients, 22 were available for PK-based main
243 Of 83
assessable patients, 46 (55%, 95% CI 44-66) achieved a s
244 Of the 56
assessable patients, 48 underwent two MRIs; 44 MRIs were
245 Of the 76
assessable patients, 74 patients (97%) suffered grade 3
246 Of 97
assessable patients, 97% responded, and 87% achieved a c
247 Focusing on the 61 late-stage (IIIB and IV)
assessable patients, a 15% partial response rate was ach
248 Among response-
assessable patients, an objective response was noted in
249 Of 16
assessable patients, best tumor responses observed were
250 Of 30 efficacy-
assessable patients, five had stable disease (SD) for at
251 The study consisted of 62 eligible and
assessable patients, median age 57 years, 41 (66.1%) hav
252 For 42
assessable patients, median plasma interleukin-6 concent
253 Among
assessable patients, response rate was 26.0% in cohort 1
254 Among 72
assessable patients, response rates of 65% and 50% were
255 In six (27%) of the 22
assessable patients, the asymptomatic BM responded to sy
256 For
assessable patients, the objective response rate (ORR) w
257 In the initially planned cohort of 100
assessable patients, the objective RR was 4% (95% CI, 1.
258 Of 48
assessable patients, the overall response rate was 31% (
259 achieved in seven (26% [95% CI 11-46]) of 27
assessable patients, with three (11% [2-29]) complete an
260 ifestations was observed in 26 (60.5%) of 43
assessable patients.
261 academic practices consecutively enrolled 89
assessable patients.
262 s (69%) and 23 partial responses (26%) in 90
assessable patients.
263 4 to 22+ months) was seen in 22 (59%) of 37
assessable patients.
264 r dose cohort (3,120 mg) was expanded to six
assessable patients.
265 redetermined recruitment stages of 20 and 40
assessable patients.
266 s 11.5% (95% CI, 6.3% to 18.9%) for response-
assessable patients.
267 mor cells was detected in 29 (81%) of the 36
assessable patients.
268 bjective response rate (RR) in the first 100
assessable patients.
269 There were no responses in 41
assessable patients.
270 a Evaluation in Solid Tumors version 1.1) in
assessable patients; those who received at least one dos
271 Approximately 70% of
assessable peptide bond hydrogens were protected from ex
272 Assessable phenotypes before any antiviral treatment inc
273 In Solid Tumors version 1.1 in the response-
assessable population (ie, patients with measurable dise
274 ecific antiviral therapy in the per-protocol
assessable population.
275 the remaining 379 patients had incompletely
assessable postoperative studies.
276 t severity, provides an objective and easily
assessable predictive parameter.
277 entrations <50 nmol/L consisted of 13 easily
assessable predictors, whereas the model for concentrati
278 In 14 (78%) of 18 Tg-
assessable PTC patients, Tg declined more than 25%.
279 cians surveyed, 535 (54%) and 378 (62%) were
assessable,
respectively.
280 Analysis of 526
assessable respondents showed a wide variation in manage
281 Moreover, 10 of 11
assessable responders who started therapy with reticulin
282 t reveal activating mutations in tumors from
assessable responding patients.
283 Early responders (67% of patients with
assessable response) achieved pCR in 35.7% compared with
284 er by fluorescent in situ hybridization (374
assessable samples), EGFR protein expression by immunohi
285 vaccine and who provided at least one valid
assessable serum sample.
286 In the response-
assessable study population (n = 47), which had a median
287 ne resistance was present in 58 (53%) of 113
assessable study sites, spread across most countries tha
288 study vaccination and provided at least one
assessable swab after baseline.
289 Six patients were not
assessable:
three discontinued study drug because of a n
290 ipheral-blood mononuclear cells at the first
assessable time point of G3139 exposure, and in eight of
291 F or RAS mutations were detected in 10 of 26
assessable tumor samples.
292 VEGF-A levels in the 17
assessable tumors were higher than in normal breast tiss
293 Ninety (60%) of 149
assessable tumors were KRAS or BRAF wild type (CAPOX, n
294 46 of 48 enrolled patients were
assessable (
two patients had unconfirmed diagnoses).
295 that included only objective preoperatively
assessable variables was developed using a multivariate
296 Eight independent preoperatively
assessable variables were identified and included in the
297 There were 24 patients, and 18 who were
assessable were enrolled.
298 Twenty-nine of 31 patients were
assessable with a variety of histologic subtypes.
299 Pain and sedation were always
assessable with excellent inter-rater reliability (numer
300 Thirty-three patients (31
assessable)
with a median age of 12 years were enrolled.